US Patent

US10537585 — Compositions comprising dexamethasone

Formulation · Assigned to Dexcel Pharma Technologies Ltd · Expires 2037-12-18 · 12y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition containing high-dose dexamethasone for treating multiple myeloma in combination with an anti-cancer drug.

USPTO Abstract

A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US10537585
Jurisdiction
US
Classification
Formulation
Expires
2037-12-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Dexcel Pharma Technologies Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.